Immune-Mediated Inflammatory Diseases: Proactive Drug Monitoring Key to Improved Disease Control with Infliximab physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
Proactive therapeutic drug monitoring with maintenance infliximab proved more effective in sustaining disease control than did standard care in patients with immune-mediated inflammatory diseases.
May 5, 2021
Therapeutic drug monitoring, half-dosing may not be ready for prime-time
Therapeutic drug monitoring (TDM) for patients with immune-mediated inflammatory diseases did not lead to better clinical remission rates, while routine dose reduction of anti-rheumatic drugs for patients with rheumatoid arthritis (RA) in remission offered modest benefits, according to two Norwegian trials.
In the NOR-DRUM Part A trial, clinical remission at week 30 was achieved in 50.5% of 198 patients with TDM versus 53% of 200 patients in the standard therapy group, for an adjusted difference of 1.5% (95% CI −8.2% to 11.1%,
P=0.78), reported Silje Watterdal Syversen, MD, PhD, of Diakonhjemmet Hospital in Oslo, and co-authors.
In the ARCTIC REWIND trial, disease flare occurred in 25% of 77 patients in the half-dose conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) group versus 6% in the stable-dose csDMARD group for a risk difference of 18% (95% CI 7%-29%), reported Si